SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL 1997 TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 272: 3240132410.
  • 2
    Chicheportiche Y, Chicheportiche R, Sizing I, Thompson J, Benjamin CB, Ambrose C, Dayer JM 2002 Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: Blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 4: 126133.
  • 3
    Wiley SR, Winkles JA 2003 TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 14: 241249.
  • 4
    Feng SLY, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, Testa JR, Peifley KA, Winkles JA 2000 The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 156: 12531261.
  • 5
    Saas P, Boucraut J, Walker PR, Quiquerez AL, Billot M, Desplat-Jego S, Chicheportiche Y, Dietrich PY 2000 TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia 32: 102107.
  • 6
    Yepes M, Brown SAN, Moore EG, Smith EP, Lawrence DA, Winkles JA 2005 A soluble fn14-fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia 1. Am J Pathol 166: 511520.
  • 7
    Campbell S, Michaelson J, Burkly L, Putterman C 2004 The role of TWEAK/Fn14 IN the pathogenesis of inflammation and systemic autoimmunity. Front Biosci 9: 22732284.
  • 8
    Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, Lee W, Hurst S, Danilenko D, Li J, Filvaroff E, Yang B, Daniel D, Ashkenazi A 2005 TWEAK attenuates the transition from innate to adaptive immunity. Cell 123: 931944.
  • 9
    Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng TS, Browning B, Michaelson JS, Baetscher M, Wang B, Bissell DM, Burkly LC 2005 TWEAK induces liver progenitor cell proliferation. J Clin Invest 115: 23302340.
  • 10
    Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, Su L, Tarilonte L, Crowell T, Rajman L, Runkel L, Scott M, Atkins GJ, Findlay DM, Zheng TS, Hess H 2006 TWEAK is a novel arthritogenic mediator. J Immunol 177: 26102620.
  • 11
    Kamata K, Kamijo S, Nakajima A, Koyanagi A, Kurosawa H, Yagita H, Okumura K 2006 Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis. J Immunol 177: 64336439.
  • 12
    Meighan-Mantha RL, Hsu DK, Guo Y, Brown SA, Feng SL, Peifley KA, Alberts GF, Copeland NG, Gilbert DJ, Jenkins NA, Richards CM, Winkles JA 1999 The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 274: 3316633176.
  • 13
    Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA 2003 The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J 371: 395403.
  • 14
    Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, Hla T, Williams MS, Winkles JA 2003 TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 23: 594600.
  • 15
    Ando T, Ichikawa J, Wako M, Hatsushika K, Watanabe Y, Sakuma M, Tasaka K, Ogawa H, Hamada Y, Yagita H, Nakao A 2006 TWEAK/Fn14 interaction regulates RANTES production, BMP-2-induced differentiation, and RANKL expression in mouse osteoblastic MC3T3-E1 cells. Arthritis Res Ther 8: R146.
  • 16
    Baron R, Rawadi G, Roman-Roman S 2006 Wnt signaling: A key regulator of bone mass. Curr Top Dev Biol 76: 103127.
  • 17
    Ott SM 2005 Sclerostin and Wnt signaling—the pathway to bone strength. J Clin Endocrinol Metab 90: 67416743.
  • 18
    Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G 2008 Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135: 825837.
  • 19
    Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C 2008 Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23: 860869.
  • 20
    Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D 2005 Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280: 1988319887.
  • 21
    Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA 2003 Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22: 62676276.
  • 22
    Winkler DG, Yu C, Geoghegan JC, Ojala EW, Skonier JE, Shpektor D, Sutherland MK, Latham JA 2004 Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J Biol Chem 279: 3629336298.
  • 23
    Winkler DG, Sutherland MS, Ojala E, Turcott E, Geoghegan JC, Shpektor D, Skonier JE, Yu C, Latham JA 2005 Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem 280: 24982502.
  • 24
    van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Lowik CW 2004 Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199: 805814.
  • 25
    van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten Dijke P, Lowik CW 2007 Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 22: 1928.
  • 26
    Jakubowski A, Browning B, Lukashev M, Sizing I, Thompson JS, Benjamin CD, Hsu YM, Ambrose C, Zheng TS, Burkly LC 2002 Dual role for TWEAK in angiogenic regulation. J Cell Sci 115: 267274.
  • 27
    Michaelson JS, Cho S, Browning B, Zheng TS, Lincecum JM, Wang MZ, Hsu YM, Burkly LC 2005 Tweak induces mammary epithelial branching morphogenesis. Oncogene 24: 26132624.
  • 28
    Staal FJ, Noort Mv M, Strous GJ, Clevers HC 2002 Wnt signals are transmitted through N-terminally dephosphorylated beta-catenin. EMBO Rep 3: 6368.
  • 29
    Atkins GJ, Kostakis P, Pan B, Farrugia A, Gronthos S, Evdokiou A, Harrison K, Findlay DM, Zannettino AC 2003 RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 18: 10881098.
  • 30
    Stewart K, Walsh S, Screen J, Jefferiss CM, Chainey J, Jordan GR, Beresford JN 1999 Further characterization of cells expressing STRO-1 in cultures of adult human bone marrow stromal cells. J Bone Miner Res 14: 13451356.
  • 31
    Quarles LD, Yohay DA, Lever LW, Caton R, Wenstrup RJ 1992 Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: An in vitro model of osteoblast development. J Bone Miner Res 7: 683692.
  • 32
    Kato Y, Windle JJ, Koop BA, Mundy GR, Bonewald LF 1997 Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner Res 12: 20142023.
  • 33
    Nakayama M, Harada N, Okumura K, Yagita H 2003 Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem Biophys Res Commun 306: 819825.
  • 34
    Atkins GJ, Kostakis P, Vincent C, Farrugia AN, Houchins JP, Findlay DM, Evdokiou A, Zannettino AC 2006 RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 21: 13391349.
  • 35
    Fazzalari NL, Kuliwaba JS, Atkins GJ, Forwood MR, Findlay DM 2001 The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. J Bone Miner Res 16: 10151027.
  • 36
    Atkins GJ, Bouralexis S, Evdokiou A, Hay S, Labrinidis A, Zannettino AC, Haynes DR, Findlay DM 2002 Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone 31: 448456.
  • 37
    Atkins GJ, Anderson PH, Findlay DM, Welldon KJ, Vincent C, Zannettino AC, O'Loughlin PD, Morris HA 2007 Metabolism of vitamin D(3) in human osteoblasts: Evidence for autocrine and paracrine activities of 1alpha,25-dihydroxyvitamin D(3). Bone 40: 15171528.
  • 38
    Findlay DM, Welldon K, Atkins GJ, Howie DW, Zannettino AC, Bobyn D 2004 The proliferation and phenotypic expression of human osteoblasts on tantalum metal. Biomaterials 25: 22152227.
  • 39
    Gronthos S, Zannettino AC, Graves SE, Ohta S, Hay SJ, Simmons PJ 1999 Differential cell surface expression of the STRO-1 and alkaline phosphatase antigens on discrete developmental stages in primary cultures of human bone cells. J Bone Miner Res 14: 4756.
  • 40
    Atkins GJ, Welldon KJ, Halbout P, Findlay DM 2008 Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 20: 653664.
  • 41
    Atkins GJ, Kostakis P, Welldon KJ, Vincent C, Findlay DM, Zannettino AC 2005 Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. J Cell Physiol 203: 573582.
  • 42
    Hu YS, Zhou H, Myers D, Quinn JM, Atkins GJ, Ly C, Gange C, Kartsogiannis V, Elliott J, Kostakis P, Zannettino AC, Cromer B, McKinstry WJ, Findlay DM, Gillespie MT, Ng KW 2004 Isolation of a human homolog of osteoclast inhibitory lectin that inhibits the formation and function of osteoclasts. J Bone Miner Res 19: 8999.
    Direct Link:
  • 43
    Lyons AB, Hasbold J, Hodgkin PD 2001 Flow Cytometric Analysis of Cell Division History Using Dilution of Carboxyfluorescein Diacetate Succinimidyl Ester, a Stably Integrated Fluorescent Probe. Academic Press, San Diego, CA, USA.
  • 44
    Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, Itoh N 2003 Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 278: 2411324117.
  • 45
    Zhang K, Barragan-Adjemian C, Ye L, Kotha S, Dallas M, Lu Y, Zhao S, Harris M, Harris SE, Feng JQ, Bonewald LF 2006 E11/gp38 selective expression in osteocytes: Regulation by mechanical strain and role in dendrite elongation. Mol Cell Biol 26: 45394552.
  • 46
    Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE 2006 Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38: 13101315.
  • 47
    Nampei A, Hashimoto J, Hayashida K, Tsuboi H, Shi K, Tsuji I, Miyashita H, Yamada T, Matsukawa N, Matsumoto M, Morimoto S, Ogihara T, Ochi T, Yoshikawa H 2004 Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. J Bone Miner Metab 22: 176184.
  • 48
    Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J 2005 Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19: 18421844.
  • 49
    Atkins GJ, Welldon KJ, Vincent C, Findlay DM 2006 Vitamin K analogues promote the differentiation of human primary osteoblasts. Calcif Tissue Int 78: S44.
  • 50
    Scholzen T, Gerdes J 2000 The Ki-67 protein: From the known and the unknown. J Cell Physiol 182: 311322.
  • 51
    Girgenrath M, Weng S, Kostek CA, Browning B, Wang M, Brown SA, Winkles JA, Michaelson JS, Allaire N, Schneider P, Scott ML, Hsu YM, Yagita H, Flavell RA, Miller JB, Burkly LC, Zheng TS 2006 TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J 25: 58265839.
  • 52
    Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR 1999 TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 274: 84558459.
  • 53
    Desplat-Jego S, Varriale S, Creidy R, Terra R, Bernard D, Khrestchatisky M, Izui S, Chicheportiche Y, Boucraut J 2002 TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J Neuroimmunol 133: 116123.
  • 54
    Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T 2006 Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin Exp Immunol 146: 540549.
  • 55
    Komori T 2006 Regulation of osteoblast differentiation by transcription factors. J Cell Biochem 99: 12331239.
  • 56
    Gilbert L, He X, Farmer P, Rubin J, Drissi H, van Wijnen AJ, Lian JB, Stein GS, Nanes MS 2002 Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 277: 26952701.
  • 57
    Galindo M, Pratap J, Young DW, Hovhannisyan H, Im HJ, Choi JY, Lian JB, Stein JL, Stein GS, van Wijnen AJ 2005 The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem 280: 2027420285.
  • 58
    Pratap J, Galindo M, Zaidi SK, Vradii D, Bhat BM, Robinson JA, Choi JY, Komori T, Stein JL, Lian JB, Stein GS, van Wijnen AJ 2003 Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res 63: 53575362.
  • 59
    Kim YJ, Kim HN, Park EK, Lee BH, Ryoo HM, Kim SY, Kim IS, Stein JL, Lian JB, Stein GS, van Wijnen AJ, Choi JY 2006 The bone-related Zn finger transcription factor Osterix promotes proliferation of mesenchymal cells. Gene 366: 145151.
  • 60
    Keller H, Kneissel M 2005 SOST is a target gene for PTH in bone. Bone 37: 148158.
  • 61
    Findlay DM, Haynes DR 2005 Mechanisms of bone loss in rheumatoid arthritis. Mod Rheumatol 15: 232240.
  • 62
    Canalis E, Economides AN, Gazzerro E 2003 Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24: 218235.
  • 63
    Chan A, van Bezooijen RL, Lowik CW 2007 A new paradigm in the treatment of osteoporosis: Wnt pathway proteins and their antagonists. Curr Opin Investig Drugs 8: 293298.
  • 64
    Doble BW, Woodgett JR 2003 GSK-3: Tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 11751186.
  • 65
    van Noort M, Meeldijk J, van der Zee R, Destree O, Clevers H 2002 Wnt signaling controls the phosphorylation status of beta-catenin. J Biol Chem 277: 1790117905.
  • 66
    ten Dijke P, Krause C, de Gorter DJ, Lowik CW, van Bezooijen RL 2008 Osteocyte-derived sclerostin inhibits bone formation: Its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am 90 (Suppl 1): 3135.
  • 67
    Caverzasio J 2008 Wnt/LRP5-independent inhibition of osteoblastic cell differentiation by sclerostin. J Bone Miner Res 23: S72.
  • 68
    Caverzasio J, Manen D 2007 Essential role of Wnt3a-mediated activation of mitogen-activated protein kinase p38 for the stimulation of alkaline phosphatase activity and matrix mineralization in C3H10T1/2 mesenchymal cells. Endocrinology 148: 53235330.
  • 69
    Yun MS, Kim SE, Jeon SH, Lee JS, Choi KY 2005 Both ERK and Wnt/beta-catenin pathways are involved in Wnt3a-induced proliferation. J Cell Sci 118: 313322.
  • 70
    Xiao G, Gopalakrishnan R, Jiang D, Reith E, Benson MD, Franceschi RT 2002 Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. J Bone Miner Res 17: 101110.
  • 71
    Palcy S, Goltzman D 1999 Protein kinase signalling pathways involved in the up-regulation of the rat alpha1(I) collagen gene by transforming growth factor beta1 and bone morphogenetic protein 2 in osteoblastic cells. Biochem J 343: 2127.
  • 72
    Celil AB, Hollinger JO, Campbell PG 2005 Osx transcriptional regulation is mediated by additional pathways to BMP2/Smad signaling. J Cell Biochem 95: 518528.
  • 73
    Higuchi C, Myoui A, Hashimoto N, Kuriyama K, Yoshioka K, Yoshikawa H, Itoh K 2002 Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J Bone Miner Res 17: 17851794.
  • 74
    Gallea S, Lallemand F, Atfi A, Rawadi G, Ramez V, Spinella-Jaegle S, Kawai S, Faucheu C, Huet L, Baron R, Roman-Roman S 2001 Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells. Bone 28: 491498.
  • 75
    Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G 2007 Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13: 156163.
  • 76
    Zhang C, Cho K, Huang Y, Lyons JP, Zhou X, Sinha K, McCrea PD, de Crombrugghe B 2008 Inhibition of Wnt signaling by the osteoblast-specific transcription factor Osterix. Proc Natl Acad Sci USA 105: 69366941.
  • 77
    Holding CA, Findlay DM, Stamenkov R, Neale SD, Lucas H, Dharmapatni AS, Callary SA, Shrestha KR, Atkins GJ, Howie DW, Haynes DR 2006 The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. Biomaterials 27: 52125219.
  • 78
    Boyce BF, Li P, Yao Z, Zhang Q, Badell IR, Schwarz EM, O'Keefe RJ, Xing L 2005 TNF-alpha and pathologic bone resorption. Keio J Med 54: 127131.